Astrazeneca stated Trixeo was now the first and only triple‑combination therapy cleared in the EU for this age group, regardless of exacerbation history, with the single‑inhaler treatment combining an ...
AstraZeneca PLC is a high-quality compounder leveraging mid-single-digit revenue growth into robust EPS gains, driven by oncology and pipeline execution. Recent EU approval of Trixeo Aerosphere for ...
Everyone has those tasks they keep putting off because dealing with them sounds worse than living with the problem for another day. Maybe it’s chasing an airline credit, sitting on hold with customer ...
- AstraZeneca AZN--secures EU approval for Trixeo Aerosphere as asthma maintenance therapy, supported by Phase III data showing reduced severe exacerbations compared to dual therapy. - The approval ...
AstraZeneca AZN announced that the European Commission has approved its respiratory drug, Trixeo Aerosphere, for a new indication. The drug is approved in the European Union (EU) as a maintenance ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
AstraZeneca (AZN) inihayag noong 23 Setyembre 2026 na ang European Commission ay nag-apruba ng Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate ...
AstraZeneca (AZN) announced on 23 September 2026 that the European Commission has approved Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate ...
Trixeo is a fixed-dose triple-combination drug (budesonide/glycopyrronium/formoterol) used as maintenence treatment for patients aged 12 or older. The drug has ...
AstraZeneca (NASDAQ: AZN) announced that the European Commission has approved its fixed-dose triple-combination inhaler Trixeo Aerosphere as a maintenance treatment for asthma in patients 12 years of ...
AstraZeneca Plc (AZN) announced that the European Commission has approved Trixeo Aerosphere as a maintenance treatment for asthma in patients aged 12 years and older whose condition is not adequately ...
AstraZeneca PLC ( AZN) Wednesday said the European Commission has approved Trixeo Aerosphere as a maintenance treatment for asthma in patients aged 12 and older who are not adequately controlled with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results